Strang THR, Gottschlich A, Cook DA, et al. - Researchers aimed at comparing the long-term safety after one negative HPV test across both DNA- and RNA-based testing assays for primary cervical cancer screening. They used data from the HPV FOCAL-DECADE cohort in order to compare the long-term cervical intraepithelial neoplasia grade 2 or higher and grade 3 or higher (CIN2+/CIN3+) outcomes of two DNA-based assays: Digene Hybrid Capture 2 High-Risk HPV DNA Test (QIAGEN; Germantown, Maryland) and cobas 4800 HPV Test (Roche; Indianapolis, Indiana), and one messenger RNA-based assay: Aptima HPV Assay (Hologic; San Diego, California). Outcomes revealed no significant difference in long-term risk of CIN2+ and CIN3+ in correlation with using DNA- vs RNA-based HPV testing assays at baseline.